Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics Bill Could Be Shaped By Waxman/Dingell Fight For House Commerce Cmte.

This article was originally published in The Pink Sheet Daily

Executive Summary

Chairmanship would give Waxman more leverage to place regulatory flexibility into the biosimilars approval pathway.

You may also be interested in...



NIH Grants Unlikely To Be In Recovery Bill, Pallone Says

Wish list for stimulus package gets airing at a hearing in Energy and Commerce’s Health Subcommittee, where Pallone and Dingell agree on priorities, though not leadership.

NIH Grants Unlikely To Be In Recovery Bill, Pallone Says

Wish list for stimulus package gets airing at a hearing in Energy and Commerce’s Health Subcommittee, where Pallone and Dingell agree on priorities, though not leadership.

Kennedy/Grassley Imports Criminal Liability To Global Drug Safety Efforts

A senior drug company officer or director would be required personally to certify the veracity of product applications and safety submissions to FDA, under Sens. Edward Kennedy, D-Mass., and Chuck Grassley's, R-Iowa, bill to improve safety in global drug manufacturing and distribution

Related Content

Topics

UsernamePublicRestriction

Register

PS067093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel